Skip to main content
Premium Trial:

Request an Annual Quote

Early Access for Oxford Nanopore PromethIon Requires $75K Deposit, $24K Access Fee

NEW YORK (GenomeWeb) – Oxford Nanopore Technologies last week outlined the early-access program for its PromethIon sequencer, including some pricing information.

The PromethIon will have higher throughput than the company's current platform, the MinIon. Instead of a single flow cell, the instrument will run up to 48 flow cells. Last month, Oxford Nanopore said it plans to introduce the platform through a similar early-access program as the MinIon, starting later this year.

According to the company's website, only early-access users of the MinIon qualify for the PromethIon Access Program, called PEAP.

To join the program, participants will need to pay a $75,000 deposit. Later on, they can use that deposit as credit to pay for flow cells, library preparation reagents, and certain workflows of the Metrichor software. Oxford Nanopore said last month that it also plans to offer pay-as-you-go pricing, where customers receive "zero hour" flow cells and pay for run time on the instrument, which can be unlocked via its software.

In addition, participants need to pay a $24,000 access fee, which will give them one PromethIon instrument, a starter pack of consumables, certain data services, and community-based support. An undisclosed number of initial participants will have their access fee waived.

Pricing information for consumables, data services, and flow cell run time, as well as the anticipated shipment date for the first PromethIon instrument, are not yet available.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.